Abstract 780P
Background
In high-grade ovarian cancer (OC) TCGA found BRCA1meth inferior to BRCAmut regarding prognosis probably due to lower sensitivity to platinum (Pt++)-based chemotherapy.
Methods
In 143 high-grade OCs tested for BRCA mutations, additionally BRCA DNA methylation was determined using MethyLight PCR and genome-wide LOH and Aneuploidy Normalized Telemetric imbalance (ANTI) by means of SNP-Array analysis (GSA-24 v 3.0/Illumina) as surrogates of genome-wide DNA-scarring. For LOH and ANTI a “clinical-threshold” was calculated by Pt++-response, determined at the first recurrence. Both were integrated in a common HRD-Score (cut-off: ≥1.912 for HRD positivity).
Results
In the present cohort, BRCA1 DNA methylation (meBRCA1) was detected in 15 (10%) and mostly BRCAwt OCs (n=14, 17%). Only one BRCA1mut OC had concomitant meBRCA1. BRCA2 DNA methylation was not observed. In terms of genomic scars, meBRCAwt and BRCAmut OCs had similar HRD scores, which were higher than those in unmethylated BRCAwt OCs (p<0.003). In BRCAwt OCs, BRCA1 methylation levels (PMR-values) were higher in HRD pos. than in HRD negative OCs (p<0.001). Progression free survival (PFS) of patients with meBRCA1 OCs was noninferior to that of BRCAmut OC patients. Worst PFS and OS was found in the subgroup of unmethylated BRCAwt OCs compared to patients with BRCAmut and meBRCA1 OCs in univariate (p=0.003; p=0.022) and multivariate survival analysis (p=0.006, p=0.018). All but one of the cancers classified as Pt++-refractory or -resistant at first relapse (92%) were unmethylated BRCAwt OCs. None of the meBRCA1 cancers were rated Pt++-refractory or -resistant, and only one BRCAmut OCs was associated with a Pt++-resistant first relapse. 98.6% of the recurrences originating from OCs with genetically or epigenetically altered BRCA genes were Pt++-sensitive, of which 77% were considered highly sensitive.
Conclusions
High-grade OCs without genetic or epigenetic BRCA alterations exhibit worst PFS. Based on genome-wide scarring, BRCA1 promotor methylation seems to exert an equivalent detrimental effect on the DNA repair by homologous recombination as pathogenic BRCA mutations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
800P - Response to chemotherapy following PARP inhibition in UK ovarian cancer (OC) patients
Presenter: Sarah Howlett
Session: Poster session 11
802P - Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study
Presenter: Frederik Marmé
Session: Poster session 11
803P - Pre-treatment systemic inflammatory markers predict survival in endometrial cancer cases: A Japanese gynaecologic oncology group 2043 exploratory data analysis
Presenter: Shin Nishio
Session: Poster session 11
805P - Tumor-informed ctDNA detection as a predictive marker for postoperative residual disease in epithelial ovarian cancer: A feasibility study
Presenter: Christoph Grimm
Session: Poster session 11
806P - Pilot ambulatory malignant bowel obstruction (MBO) electronic monitoring program in patients with gynecologic cancers
Presenter: Ainhoa Madariaga Urrutia
Session: Poster session 11
807P - Predicting surgical outcomes in patients with advanced ovarian cancer through MRI based preoperative evaluation
Presenter: Shujuan Liu
Session: Poster session 11
808P - Cell-free human papillomavirus (HPV) DNA is a sensitive biomarker for monitoring treatment response and for detecting relapse in locally advanced cervical cancer
Presenter: Lars Sivars
Session: Poster session 11
809P - Mental and socioeconomic burden in endometrial and cervical cancer patients: A Swedish population-based study of survivorship
Presenter: jiangrong wang
Session: Poster session 11
810P - The influence of preoperative conization (pc) to patient’s (pts) outcome and tumor biology of cervical cancer (CC)
Presenter: Dimitra Trantaki
Session: Poster session 11
811P - Epidemiological landscape of cervical cancer in Latin America: EVITA LATAM (LACOG 0820)
Presenter: Graziela Zibetti Dal Molin
Session: Poster session 11